Microsoft word - 130329 publications aa

Bernard C, Maucort-Boulch D, Varron L, Charlier C, Sitbon K, Freymond N, Bouhour D, Hot A, Masquelet AC, Valeyre D, Costedoat-Chalumeau N, Etienne M, Gueit I, Jouneau S, Delaval P, Mouthon L, Pouget J, Serratrice J, Brion JP, Vaylet F, Bremont C, Chennebault JM, Jaffuel S, Broussolle C, Lortholary O & Seve P. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. Qjm, In press. Bernard J, Poulalhon N, Argenziano G, Debarbieux S, Dalle S & Thomas L. Dermoscopy of dermatofibrosarcoma protuberans: a study of 15 cases. Br J Dermatol, In press. Brackers de Hugo L, Ffrench M, Broussolle C & Seve P. Granulomatous lesions in bone marrow. Clinicopathologic findings and significance in a study of 48 cases. Eur J Intern Med, In press. Carrera C, Bennassar A, Ishioka P, Dalle S, Vilalta A, Fuertes I, Alos L, Thomas L, Puig S & Malvehy J. Desmoplastic melanoma on the nose: electrochemotherapy as an alternative treatment to local advanced disease. J Eur Acad Dermatol Venereol, In press. Dalle S, Poulalhon N, Debarbieux S & Thomas L. Second primary melanomas under vemurafenib. Br J Debarbieux S, Dalle S, Depaepe L, Poulalhon N, Balme B & Thomas L. Second primary melanomas under BRAF blockers: study by Reflectance Confocal Microscopy. Br J Dermatol, In press. Doleans-Jordheim A, Veron JB, Fendrich O, Bergeron E, Montagut-Romans A, Wong YS, Furdui B, Freney J, Dumontet C & Boumendjel A. 3-Aryl-4-methyl-2-quinolones Targeting Multiresistant Staphylococcus aureus Bacteria. ChemMedChem, In press. Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C & Seve P. Myositis in a patient with Familial Mediterranean Fever and spondyloarthritis successfully treated with Anakinra. Joint Bone Spine, In press. Goutelle S, Baudry T, Gagnieu MC, Boibieux A, Livrozet JM, Peyramond D, Chidiac C, Tod M & Ferry T. Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients. Antimicrob Agents Chemother, In press. Grange F, Barbe C, Aubin F, Lipsker D, Granel-Brocard F, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, Dalle S, Bernard P & Woronoff AS. Clinical and socio-demographic characteristics of thick melanomas: a population-based, case-case study. Archives of Dermatology, In press. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terre C, Guardiola P, Bene MC, Preudhomme C, Ifrah N & Dombret H. Prospective evaluation of gene mutations and minimal residual disease (MRD) in patients with core binding factor acute myeloid leukemia (CBF-AML). Blood, In press. Leroy S, Gaudebout N, Lanteme P & Seve P. Recurrent pericarditis as an initial manifestation of Wegener's granulomatosis. Ann Cardiol Angeiol (Paris), In press. Levy-Sitbon C, Barbe C, Granel-Brocard F, Lipsker D, Aubin F, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Le Clainche A, Dalle S, Bernard P & Grange F. Diagnosis and management of melanoma with regional lymph node metastases: a population-based study in France. J European Acad dermatol, In press. Martino A, Sainz J, Manuel Reis R, Moreno V, Buda G, Lesueur F, Marques H, Garcia-Sanz R, Rios R, Stein A, Dumontet C, Gemignani F, Maria Rossi A, Landi S, Jurado M, Petrini M, Jamroziak K, Campa D & Canzian F. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. J Hum Genet, In press. Reslan L, Dalle S, Herveau S, Perrial E, Tournebize C & Dumontet C. Comparison of the cytotoxic mechanism of anti-CD20 antibodies rituximab and GA101 against fresh chronic lymphocytic leukemia cells. Leuk Lymphoma, In press. Saadoun D, Bodaghi B, Bienvenu B, Wechsler B, Sene D, Trad S, Abad S, Cacoub P, Kodjikian L & Seve P. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev, In press. Tagoug I, Plesa A & Dumontet C. Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol, In press. Tredan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C & Menetrier-Caux C. Patients with metastatic breast cancer leading to CD4+ T cell lymphopenia have poor outcome. Eur J Cancer, In press. Tredan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J & Ray-Coquard I. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol, In press. Almouazen E, Bourgeois S, Jordheim LP, Fessi H & Briancon S. Nano-encapsulation of Vitamin D3 Active Metabolites for Application in Chemotherapy: Formulation Study and in Vitro Evaluation. Pharm Res, 2013, 30, (4): 1137-1146. Buron F, Malvezzi P, Villar E, Chauvet C, Janbon B, Denis L, Brunet M, Daoud S, Cahen R, Pouteil- Noble C, Gagnieu MC, Bienvenu J, Bayle F, Morelon E & Thaunat O. Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study. PLoS One, 2013, 8, (1): e53078. Carrabin N, Treilleux I, Meeus P, Tredan O & Ray-Coquard I. Primary ovarian borderline tumor in the inguinal lymph node. Int J Gynecol Pathol, 2013, 32, (2): 167-170. Clerc J, Sunyach MP, Duruisseaux M, Mignotte H, Bajard A, Tredan O & Arnaud A. Regional recurrence of triple-negative breast cancer: Interest of systematic adjuvant lymph node irradiation? Gynecol Obstet Fertil, 2013, 41, (2): 90-95. Debarbieux S, Depaepe L, Poulalhon N, Balme B, Dalle S & Thomas L. Reflectance confocal microscopy accurately discriminates between benign and malignant melanocytic lesions exhibiting a 'dermoscopic island'. J Eur Acad Dermatol Venereol, 2013, 27, (2): e159-165. Debarbieux S, Depaepe L, Poulalhon N, Dalle S, Balme B & Thomas L. Reflectance confocal microscopy characteristics of eight cases of pustular eruptions and histopathological correlations. Skin Res Technol, 2013, 19, (1): e444-452. Deshayes E, Le Berre JP, Jouanneau E, Vasiljevic A, Raverot G & Seve P. 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med, 2013, 38, (1): e50-52. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E & Leroy V. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol, 2013, 56, (2): 146-149. Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin ML, Thomas X, Tiberghien P, Simpson E, Rigal D & Scott D. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone. J Immunol, 2013, 190, (1): 184-194. Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terre C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S & Dombret H. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol, 2013, 31, (3): 321-327. Gupta V, Richards S, Rowe J & with Thomas X. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood, 2013, 121, (2): 339-350. Jordheim LP, Marton Z, Rhimi M, Cros-Perrial E, Lionne C, Peyrottes S, Dumontet C, Aghajari N & Chaloin L. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening. Biochem Pharmacol, 2013, 85, (4): 497-506. Massa AF, Dalle S & Thomas L. Subcorneal hematoma. Ann Dermatol Venereol, 2013, 140, (1): 63-64. Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussiere H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE & Jaisson-Hot I. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer, 2013, 119, (1): 107-114. Moulin C, Poulalhon N, Duru G, Debarbieux S, Dalle S & Thomas L. Dermoscopy use by French private practice dermatologists: a nationwide survey. Br J Dermatol, 2013, 168, (1): 74-79. Pavic M, Pasquet F, Fieschi C, Malphettes M & Seve P. Granulomatosis and primary immunodeficiency in the adulthood. Rev Med Interne, 2013, 34, (3): 154-158. Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C & Blay JY. CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer, 2013, 49, (5): 1080-1089. Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricala C, Dalle S, Duval- Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA & Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet, 2013, 50, (4): 264-270. Seve P, Broussolle C & Pavic M. Primary immunodeficiencies presenting with autoimmune cytopenias in adults. Rev Med Interne, 2013, 34, (3): 148-153. Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M, Huguet F, Rea D, Delannoy A, Cahn JY, Vernant JP, Ifrah N, Dombret H & Thomas X. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant, 2013, 19, (1): 150-155. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H & Harousseau JL. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med, 2012, 366, (19): 1782-1791. Bally C, Fadlallah J, Leverger G, Bertrand Y, Robert A, Baruchel A, Guerci A, Recher C, Raffoux E, Thomas X, Leblanc T, Idres N, Cassinat B, Vey N, Chomienne C, Dombret H, Sanz M, Fenaux P & Ades L. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. J Clin Oncol, 2012, 30, (14): 1641-1646. Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C & Tuszynski JA. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One, 2012, 7, (12): e51329. Bernard C, Kodjikian L, Bancel B, Isaac S, Broussolle C & Seve P. Ocular sarcoidosis: when should labial salivary gland biopsy be performed? Graefes Arch Clin Exp Ophthalmol, 2012, 251, (3): 855-860. Boespflug A, Dalle S & Thomas L. Melanoma mimicking Reed naevus. Ann Dermatol Venereol, 2012, Bouaziz A, Le Scanff J, Chapelon-Abric C, Varron L, Khenifer S, Gleizal A, Bentz MH, Barthel A, Valeyre D & Seve P. Oral involvement in sarcoidosis: report of 12 cases. Qjm, 2012, 105, (8): 755-767. Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupre N & Berger MG. Measurement of imatinib uptake by flow cytometry. Cytometry A, 2012, 81, (11): 996-1004. Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, Cieslak A, Minard-Colin V, Rullier A, Moreau A, Baruchel A, Schmitt C, Asnafi V, Bertrand Y & Macintyre E. Clinical Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric T-Cell Lymphoblastic Lymphoma. J Clin Oncol, 2012, 30, (16): 1966-1973. Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Vieira Reis RM, Garcia-Sanz R, Jurado M, Rios R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, Landi S & Canzian F. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. Br J Haematol, 2012, 157, (3): 331-338. Cannas G, Pautas C, Raffoux E, Quesnel B, Botton S, Revel T, Reman O, Gardin C, Elhamri M, Boissel N, Fenaux P, Michallet M, Castaigne S, Dombret H & Thomas X. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma, 2012, 53, (6): 1068-1076. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S & Dombret H. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet, 2012, 379, (9825): 1508-1516. Dalle S, Finet A & Thomas L. Kaposi's sarcoma. Ann Dermatol Venereol, 2012, 139, (1): 73-74. Dalle S, Parmentier L, Moscarella E, Phan A, Argenziano G & Thomas L. Dermoscopy of merkel cell carcinoma. Dermatology, 2012, 224, (2): 140-144. Detrait M, Dubois V, Sobh M, Morisset S, Tedone N, Labussiere H, Gillis L, Barraco F, Cannas G, Ducastelle S, Fatoum J, Thomas X, Chelgoum Y, Nicolini FE & Michallet M. Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens. Exp Hematol, 2012, 40, (10): 792-799. Dufour JF, Le Gallou T, Cordier JF, Aumaitre O, Pinede L, Aslangul E, Pagnoux C, Marie I, Puechal X, Decaux O, Dubois A, Agard C, Mahr A, Comoz F, Boutemy J, Broussolle C, Guillevin L, Seve P & Bienvenu B. Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. Medicine (Baltimore), 2012, 91, (2): 67-74. Dupire S, Wemeau M, Debarri H, Pascal L, Hivert B, Willekens C, Boyle E, Manier S, Beatrice T, Onraed B, Faucompre JL, Hennache B, Dumontet C, Facon T & Leleu X. Prognostic value of PINI index in patients with multiple myeloma. Eur J Haematol, 2012, 88, (4): 306-313. Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, Burtey S, Chiche L, Serratrice J, Longy- Boursier M, Ruivard M, Haroche J, Godeau B, Beucher AB, Berthelot JM, Papo T, Pennaforte JL, Benyamine A, Jourde N, Landron C, Roblot P, Moranne O, Silvain C, Granel B, Bernard F, Veit V, Mazodier K, Bernit E, Rousset H, Boucraut J, Boffa JJ, Weiller PJ, Kaplanski G, Aucouturier P, Harle JR & Schleinitz N. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore), 2012, 91, (1): 49-56. Ferry T, Senechal A, Gagnieu MC, Boibieux A, Laurent F, Perpoint T, Tod M & Chidiac C. Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection. J Infect, 2012, 65, (6): 579-582. Giebel S, Thomas X, Hallbook H, Geissler K, Boiron JM, Huguet F, Koller E, Jaeger U, Smedmyr B, Hellmann A & Holowiecki J. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL. Eur J Cancer, 2012, 48, (3): 360-367. Gomez-Abreo D, Prost C, Couraud S, Parmeland L, Carret G, Boibieux A, Gagnieu MC, Geriniere L, Avrillon V & Souquet PJ. Chronic necrotizing pulmonary aspergillosis following an infection by Mycobacterium malmoense. Rev Mal Respir, 2012, 29, (3): 435-439. Goncalves A, Tredan O, Villanueva C & Dumontet C. Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1). Bull Cancer, 2012, 99, (12): 1183-1191. Grange F, Barbe C, Mas L, Granel-Brocard F, Lipsker D, Aubin F, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, Dalle S, Reuter G, Bernard P, Woronoff AS & Arnold F. The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France. Br J Dermatol, 2012, 167, (6): 1351-1359. Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, Cornillet- Lefebvre P, Plesa A, Huet S, Renneville A, Salles G, Nicolini FE, Magaud JP & Michallet M. High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. PLoS One, 2012, 7, (12): e51527. Hospital MA, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, Bourhis JH, Reman O, de Revel T, Terre C, Preudhomme C, Fenaux P, Michallet M, Socie G & Dombret H. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow Transplant, 2012, 47, (11): 1436-1441. Joly P, Gagnieu MC, Bardel C, Francina A, Pondarre C & Martin C. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol, 2012, 87, (5): 534-536. Jordheim LP, Ben Larbi S, Fendrich O, Ducrot C, Bergeron E, Dumontet C, Freney J & Doleans- Jordheim A. Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. Int J Antimicrob Agents, 2012, 39, (5): 444-447. Julia F, Thomas L & Dalle S. New therapeutical strategies in the treatment of metastatic disease. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysak D, Minden M & Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol, 2012, 30, (21): 2670-2677. Langrand C, Bihan H, Raverot G, Varron L, Androdias G, Borson-Chazot F, Brue T, Cathebras P, Pinede L, Muller G, Broussolle C, Cotton F, Valeyre D & Seve P. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. Qjm, 2012, 105, (10): 981-995. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, Deangelo DJ, Giles FJ & Marie JP. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs, 2012, 30, (3): 1121-1131. Le MP, Solas C, Garraffo R, Gagnieu MC, Muret P, Yeni P, Dhiver C, Katlama C, Poizot-Martin I, Durant J & Peytavin G. Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor. J Antimicrob Chemother, 2012, 67, (11): 2779-2781. Le Tourneau C, Kamal M, Tredan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T & Paoletti X. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol, 2012, 7, (4): 253-265. Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N & Menetrier-Caux C. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology, 2012, 1, (4): 432-440. Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier- Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andre T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Deviere J, Emile JF & Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology, 2012, 143, (3): 664-674 e666. Martino A, Campa D, Buda G, Sainz J, Garcia-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Rios R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F & Rossi AM. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Leukemia, 2012, 26, (6): 1419-1422. Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, Garcia-Sanz R, Lesueur F, Marques H, Moreno V, Jurado M, Rios R, Szemraj-Rogucka Z, Szemraj J, Tjonneland A, Overvad K, Vangsted AJ, Vogel U, Mikala G, Kadar K, Szombath G, Varkonyi J, Orciuolo E, Dumontet C, Gemignani F, Rossi AM, Landi S, Petrini M, Houlston RS, Hemminki K & Canzian F. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. Br J Haematol, 2012, 158, (6): 805-809. Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, Garcia-Sanz R, Jurado M, Rios R, Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S, Rossi AM, Dumontet C, Petrini M, Campa D & Canzian F. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J Oncol, 2012, 40, (3): 625-638. Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, Dalle S, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita L, Martin L, Crickx B, Joly P, Thomas L, Bressac-de Paillerets B, Avril MF & Demenais F. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol, 2012, 67, (6): 1257-1264. Michallet M, Benet T, Sobh M, Kraghel S, El Hamri M, Cannas G, Nicolini FE, Labussiere H, Ducastelle S, Barraco F, Thomas X, Chelghoum Y, Nicolle MC, Bienvenu AL, Persat F, De Monbrison F, Picot S & Vanhems P. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis, 2012, 31, (6): 991-997. Miller LM, Huang Yang CP, Xiao H, Isaac S, Seve P, Dumontet C, Band Horwitz S & Hogue Angeletti R. A label-free mass spectrometry method for relative quantitation of beta-tubulin isotype expression in human tumor tissue. Proteomics Clin Appl, 2012, 6, (9-10): 502-506. Milley S, Bories N, Balme B, Thomas L & Dalle S. Indolent CD8+ lymphoid proliferation on the nose. Ann Dermatol Venereol, 2012, 139, (12): 812-817. Pasquet F, Kodjikian L, Mura F, Riviere S, Harroche J, Blanc AP, Chaix F, Oksenhendler E & Seve P. Uveitis and common variable immunodeficiency: data from the DEF-I study and literature review. Ocul Immunol Inflamm, 2012, 20, (3): 163-170. Pauwels PJ, Dumontet C, Reichert JM, Beck A, Goetsch L, Corvaia N, Klein C, Coiffier B & Teicher B. 7th cancer scientific forum of the canceropole lyon auvergne rhone-alpes: march 20-21, 2012, lyon, france. MAbs, 2012, 4, (4): 434-444. Peron J, Tredan O, Ray-Coquard I, Bachelot T, Labidi Galy SI, Favier B, Treilleux I & Guastalla JP. First- line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. Bull Cancer, 2012, 99, (2): E18-25. Peyrouze P, Guihard S, Grardel N, Berthon C, Pottier N, Pigneux A, Cahn JY, Bene MC, Lheritier V, Delabesse E, Macintyre E, Thomas X, Dombret H, Ifrah N & Cheok M. Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. Br J Haematol, 2012, 159, (5): 599-613. Poulard C, Treilleux I, Lavergne E, Bouchekioua-Bouzaghou K, Goddard-Leon S, Chabaud S, Tredan O, Corbo L & Le Romancer M. Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol Med, 2012, 4, (11): 1200-1213. Pralong P, Bathelier E, Dalle S, Poulalhon N, Debarbieux S & Thomas L. Dermoscopy of lentigo maligna melanoma: report of 125 cases. Br J Dermatol, 2012, 167, (2): 280-287. Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honore S, Aci-Seche S, Grierson D, Antonipillai J, Li R, Di Pietro A, Dumontet C, Braguer D, Florent JC, Knapp S, Bernard O & Lafanechere L. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res, 2012, 72, (17): 4429-4439. Rahmi A, Deshayes E, Maucort-Boulch D, Varron L, Grange JD, Kodjikian L & Seve P. Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography. Br J Ophthalmol, 2012, 96, (1): 99-103. Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP & Seve P. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol, 2012, 23, (1): 86-93. Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton S, Revel T, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H & Preudhomme C. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia, 2012, 26, (6): 1247-1254. Rhondali W, Perceau E, Berthiller J, Saltel P, Trillet-Lenoir V, Tredan O, Coulon JP, Bruera E & Filbet M. Frequency of depression among oncology outpatients and association with other symptoms. Support Care Cancer, 2012, 20, (11): 2795-2802. Rhondali W, Perceau E, Saltel P, Trillet-Lenoir V, Blay JY, Fournel-Federico C, Coulon JP, Tredan O, Terra JL, Matillon Y, Bruera E & Filbet M. Depression assessment by oncologists and palliative care physicians. Palliat Support Care, 2012: 1-9. Rivet C, Caron N, Lachaux A, Morel B, Pracros JP, Francina A, Gagnieu MC & Joly P. Association of a glucose-6-phosphate deficiency and a Gilbert syndrome as risk factors for a severe choledocholithiasis in a 2-month-old male infant. Pediatr Blood Cancer, 2012, 58, (2): 316. Romieu I, Touillaud M, Ferrari P, Bignon YJ, Antoun S, Berthouze-Aranda S, Bachmann P, Duclos M, Ninot G, Romieu G, Senesse P, Behrendt J, Balosso J, Pavic M, Kerbrat P, Serin D, Tredan O & Ferverts B. Activité physique et survie après cancer. Bull Cancer, 2012, 99, (10): 979-994. Schmitt C, Bouteille C, Faure C, Mignotte H, Tredan O, Bachelot T, Guastalla JP, Arnaud A, Treilleux I & Carrabin N. Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node. Bull Cancer, 2012, 99, (4): 463-469. Seve P, Varron L, Broussolle C, Denis P & Kodjikian L. Sarcoid-related Uveitis Occurring During Adalimumab Therapy. Ocul Immunol Inflamm, 2012, 20, (1): 59-60. Solas C & Gagnieu MC. Evidence-based Therapeutic Drug Monitoring for Efavirenz. Therapie, 2012, Thomas X. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs, 2012, 21, (6): 871-878. Thomas X. Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy. World J Stem Cells, 2012, 4, (6): 44-52. Thomas X. DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opin Drug Discov, 2012, 7, (11): 1039-1051. Thomas X. Intérêt du priming dans le traitement de la leucémie aiguë myéloïde. Hématologie, 2012, Thomas X. Acute myeloid leukemia in the elderly. International Journal of Hematologic Oncology, Thomas X. Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias. Blood and Lymphatic Cancer: Targets and Therapy, 2012, 2: 57-76. Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P, Preudhomme C, Socie G, Michallet M, Castaigne S & Dombret H. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. Leuk Res, 2012, 36, (9): 1112-1118. Varron L, Cottin V, Schott AM, Broussolle C & Seve P. Late-onset sarcoidosis: a comparative study. Medicine (Baltimore), 2012, 91, (3): 137-143. Villani AP, Thomas L & Dalle S. Pectoral nodule: nodular melanoma. Ann Dermatol Venereol, 2012, Zeinyeh W, Mahiout Z, Radix S, Lomberget T, Dumoulin A, Barret R, Grenot C, Rocheblave L, Matera EL, Dumontet C & Walchshofer N. Progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation. Steroids, 2012, 77, (12): 1177-1191. Androdias G, Maillet D, Marignier R, Pinede L, Confavreux C, Broussolle C, Vukusic S & Seve P. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology, 2011, 76, (13): 1168-1172. Aouali N, El Btaouri H, Dumontet C, Eddabra L, Malagarie-Cazenave S, Madoulet C & Morjani H. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. Oncol Rep, 2011, 25, (4): 1161-1167. Arnaud O, Boumendjel A, Geze A, Honorat M, Matera EL, Guitton J, Stein WD, Bates SE, Falson P, Dumontet C, Di Pietro A & Payen L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. Eur J Cancer, 2011, 47, (4): 640-648. Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, Tredan O, Labidi Galy I, Moullet I, Ardisson P, Vincent L, Coeffic D, Dufresne A, Bergerat JP & Ray-Coquard I. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. Bull Cancer, 2011, 98, (9): 80-89. Baleydier F, Domenech C & Thomas X. Novel conventional therapies in onco-hemathology. Bull Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P, Thomas X, Lepretre S, Huguet F, Vey N, Escoffre-Barbe M, Tavernier E, Reman O, Fegueux N, Turlure P, Rousselot P, Cahn JY, Lheritier V, Chalandon Y, Bene MC, Macintyre E, Dombret H & Ifrah N. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood, 2011, 118, (19): 5099-5107. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardiere A, Molinie V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugieres L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanche H, Zelenika D, Galan P, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fetita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Mateus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R & Bressac-de Paillerets B. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, (7375): 94-98. Caprano V, Zane L, Poncet D, Galia P, Preudhomme C, Bonnefoy-Berard N, Gilson E, Thomas X, Elhamri M, Chelghoum Y, Michallet M, Wattel E, Mortreux F & Sibon D. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol, 2011, 39: 195-202. Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Menetrier-Caux C, Tredan O, Goddard-Leon S, Pin JJ, Mignotte H, Bathelemy-Dubois C, Caux C, Lebecque S & Blay JY. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer, 2011, 11: 213. Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, Mahon FX, Dumontet C, Puisieux A, Nicolini FE & Maguer-Satta V. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood, 2011, 117, (5): 1673-1676. Dalle S, Poulalhon N & Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 365, (15): 1448-1449; author reply 1450. Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C & Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther, 2011, 10, (1): 178-185. Dalle S, Sureda N & Thomas L. Pigmented lesion on the left breast. Ann Dermatol Venereol, 2011, Dalle S, Thomas L & Shear NH. How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology. Int J Dermatol, 2011, 50, (1): 114-118. Doleans-Jordheim A, Bergeron E, Bereyziat F, Ben-Larbi S, Dumitrescu O, Mazoyer MA, Morfin F, Dumontet C, Freney J & Jordheim LP. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur J Clin Microbiol Infect Dis, 2011, 30, (10): 1249-1256. Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D & Bertrand Y. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol, 2011, 153, (1): 58-65. Dumontet C. Antitubulin agents. Bull Cancer, 2011, 98, (11): 1275-1285. Gallier F, Lallemand P, Meurillon M, Jordheim LP, Dumontet C, Perigaud C, Lionne C, Peyrottes S & Chaloin L. Structural Insights into the Inhibition of Cytosolic 5'-Nucleotidase II (cN-II) by Ribonucleoside 5'-Monophosphate Analogues. PLoS Comput Biol, 2011, 7, (12): e1002295. Galy G, Labidi-Galy SI, Perol D, Bachelot T, Ray-Coquard I, Tredan O, Biron P, Latour JF, Blay JY, Guastalla JP & Favier B. Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. Breast Cancer Res Treat, 2011, 128, (1): 187-195. Gillibert-Duplantier J, Duthey B, Sisirak V, Salaun D, Gargi T, Tredan O, Finetti P, Bertucci F, Birnbaum D, Bendriss-Vermare N & Badache A. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene, 2011, 31, (30): 3516-3524. Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard M, Seve P, Smail A, Viallard JF, Godeau B, Hermine O & Michel M. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol, 2011, 155, (4): 498-508. Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, Dumontet C, Michallet M & Thomas X. Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases. Leuk Res, 2011, 35, (8): 1027-1031. Hage-Sleiman R, Herveau S, Matera EL, Laurier JF & Dumontet C. Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells. Mol Cancer Ther, 2011, 10, (2): 303-312. Heudel PE, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP & Bachelot T. Antihormonal therapy in breast cancer and mTOR inhibitors. Bull Cancer, 2011, 98, (12): 1431-1437. Honorat M, Falson P, Terreux R, Di Pietro A, Dumontet C & Payen L. Multidrug resistance ABC transporter structure predictions by homology modeling approaches. Curr Drug Metab, 2011, 12, (3): 268-277. Honorat M, Mesnier A, Vendrell J, Di Pietro A, Lin V, Dumontet C, Cohen P & Payen L. MRP8/ABCC11 expression is regulated by dexamethasone in breast cancer cells and is associated to progesterone receptor status in breast tumors. Int J Breast Cancer, 2011, 2011: 807380. Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhedin N, Delannoy A, Lafage-Pochitaloff M, Bene MC, Ifrah N & Dombret H. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica, 2011, 96, (2): 245-252. Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terre C, Fenaux P, Castaigne S, Dombret H & Boissel N. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica, 2011, 96, (6): 837-844. Jordheim LP. Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients. Leuk Res, 2011, 35, (4): 429-430. Jordheim LP, Plesa A, Dreano M, Cros-Perrial E, Keime C, Herveau S, Demangel D, Vendrell JA & Dumontet C. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. Cancer Chemother Pharmacol, 2011, 68, (1): 97-105. Jordheim LP, Seve P, Tredan O & Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol, 2011, 12, (7): 693-702. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, Tredan O, Durand I, Menetrier-Caux C, Caux C, Blay JY, Ray-Coquard I & Bendriss-Vermare N. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res, 2011, 71, (16): 5423-5434. Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, Bienvenu AL, Picot S, Nicolle MC & Vanhems P. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol, 2011, 49, (7): 681-687. Nguyen AM, Seve P, Le Scanff J, Gambrelle J, Fleury J, Broussolle C, Grange JD & Kodjikian L. Clinical and etiological aspects of uveitis: a retrospective study of 121 patients referred to a tertiary centre of ophthalmology. Rev Med Interne, 2011, 32, (1): 9-16. Nguyen-Dumont T, Jordheim LP, Michelon J, Forey N, McKay-Chopin S, Sinilnikova O, Le Calvez-Kelm F, Southey MC, Tavtigian SV & Lesueur F. Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2. BMC Med Genomics, 2011, 4: 39. Nicolle MC, Benet T, Thiebaut A, Bienvenu AL, Voirin N, Duclos A, Sobh M, Cannas G, Thomas X, Nicolini FE, De Monbrison F, Piens MA, Picot S, Michallet M & Vanhems P. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica, 2011, 96, (11): 1685-1691. Phan A, Dalle S, Marcilly MC, Bergues JP & Thomas L. Benign dermoscopic parallel ridge pattern variants. Arch Dermatol, 2011, 147, (5): 634. Phan A, Dalle S & Thomas L. Hairpin vessels. Ann Dermatol Venereol, 2011, 138, (6-7): 542-544. Plesa A, Thomas X, Le QH, Michallet AS, Dubois V, Dumontet C & Michallet M. A comparison of flow cytometry detection of minimal residual disease and chimerism kinetics in chronic lymphocytic leukemia patients after allogeneic hematopoietic stem cell transplantation. J Biomed Sci Eng, 2011, 4: 173-179. Puech R, Gagnieu MC, Planus C, Charpiat B, Boibieux A, Ferry T & Tod M. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir. Br J Clin Pharmacol, 2011, 71, (4): 621-623. Renneville A, Boissel N, Helevaut N, Nibourel O, Terre C, Pautas C, Gardin C, Thomas X, Turlure P, Reman O, Berthon C, Dombret H, Castaigne S & Preudhomme C. Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia. Leukemia, 2011, 25, (12): 1918-1921. Rolin MA, Kodjikian L, Varron L, Nguyen AM, Grange JD, Broussolle C & Seve P. Characteristics of uveitis presenting for the first time in the elderly: analysis of 91 patients in a tertiary center. Ocular Immunol Inflamm, 2011, 19: 219-226. Seve P & Lega JC. Kawasaki disease in adult patients. Rev Med Interne, 2011, 32, (1): 17-25. Seve P & Pavic M. Sarcoidosis: What's new in 2010 for internists? Rev Med Interne, 2011, 32, (2): 71- Sureda N, Phan A, Poulalhon N, Balme B, Dalle S & Thomas L. Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review. Br J Dermatol, 2011, 165, (4): 852-858. Sureda N, Thomas L, Bathelier E, Balme B, Depaepe L & Dalle S. Bullous lymphomatoid papulosis. Clin Tagoug I, Sauty De Chalon A & Dumontet C. Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One, 2011, 6, (7): e22641. Thomas X. Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia? Bull Cancer, 2011, 98, (7): 761-767. Thomas X. Chapter 16: Induction therapy in adult acute lymphoblastic leukemia. In: Leukemias: Principles and Practice of Therapy. Edited by Faderl S, Kantarjian H. Blackwell Publishing Ltd. 193-216: 193-216. Thomas X & Chelghoum Y. Promyelocytic sarcoma of the sternum: a case report and review of the literature. Korean J Hematol, 2011, 46, (1): 52-56. Thomas X & Chelghoum Y. Lenalidomide in elderly acute myeloid leukemia (AML) patients with deletion 5q [del(5q)]. Blood e-letter, 2011. Thomas X, Chelghoum Y, Cannas G, Elhamri M, Labussiere H, Tigaud I, Ducastelle S, Nicolini F, Dumontet C & Michallet M. Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making? Clin Lymphoma Myeloma Leuk, 2011, 11, (4): 342-349. Thomas X, Chelghoum Y, Fanari N & Cannas G. Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies. Hematology, 2011, 16, (5): 278-283. Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S & Dombret H. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood, 2011, 118, (7): 1754-1762. Tod M, Goutelle S & Gagnieu MC. Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. Clin Pharmacol Ther, 2011, 90, (4): 582-587. Tredan O, Ray-Coquard I, Arnaud A, Racadot S & Guastalla JP. Cervix cancer and corpus cancer of the uterus. Rev Prat, 2011, 61, (10): 1435-1442. Tredan O, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, Perol D, Saba C, Quiblier F, Blay JY & Bachelot T. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer, 2011, 11: 95. Vallin M, Guillaud O, Morard I, Gagnieu MC, Mentha G, Adham M, Morelon E, Boillot O, Giostra E & Dumortier J. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant, 2011, 25, (4): 660-669. Varron L, Abad S, Kodjikian L & Seve P. Sarcoid uveitis: Diagnostic and therapeutic update. Rev Med Varron L, Vignes S, Green L, Morelec I, Broussolle C & Seve P. Recurrent lymphangiectasia of the left supraclavicular fossa: an unusual cause of paroxystic swelling. Arch Dermatol, 2011, 147, (11): 1337-1338.


Microsoft word - metabolicsyndromepart2 02.doc

Thyroid Hormones and Equine Metabolic Syndrome In the main article on equine metabolic syndrome (aka insulin resistance), I mentioned in passing that sometimes thyroid hormone supplementation is used to assist in weight reduction with these overweight, laminitis-prone horses. In this article I thought I’d discuss that in a bit more detail. The thyroid gland First, a brief descriptio

Beecktechn agl2 engl.qxt

BEECKtechn AGL2 engl.qxt 04.05.2001 18:26 Uhr Seite 25 NATURAL PAINTS BEECK’sche FARBWERKE Technical Information Sheet, Rev. 04/2001 AGLAIA RENOVATION PLASTER Ready-to-use, fiber-reinforced leveling plaster, especially for creating fine plaster-like surfaces indoors. Sound-absorbent and excellent absorption capacity regarding humidity and airborne pollutants. For application and tex

Copyright ©2018 Sedative Dosing Pdf